A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA

Trial Profile

A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Spebrutinib (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Acronyms CLEAR
  • Most Recent Events

    • 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2019 to 1 Jun 2018.
    • 20 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Nov 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top